Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...

Melanoma is the most common form of skin cancer, but for patients with advanced melanoma who no longer respond to standard ...

MAIA also announced that it has enrolled five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 trial. Screening for the trial is ongoing in Europe and Asia. With ...

Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of DT-7012, a ...

Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. Genmab and BioNTech SE are ...

OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for gotistobart (BNT316/ONC392) for the treatment of patients with ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announced that the first patients have been ...

Inflammation is a critical component of the immune response that plays a pivotal role in maintaining tissue homeostasis.

CREATE Medicines, Inc., formerly Myeloid Therapeutics, Inc. ("CREATE"), announced today that Amsterdam University Medical Center ("Amsterdam UMC") has dosed the first patient in the SPaCE-MT clinical ...

Hepatocellular carcinoma (HCC) represents a leading cause of cancer-related mortality globally. The advent of immunotherapy, particularly immune checkpoint ...